Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8729911 | Journal of Visceral Surgery | 2018 | 9 Pages |
Abstract
The management of patients with pancreatic neuroendocrine tumor (PNET), whether hormonally secretory or not, is multidisciplinary and often multimodal. Surgical treatment plays a central role because complete resection is the only potentially curative treatment. The choice of the therapeutic plan for a PNET requires precise localization of the primary tumor (which may sometimes be multiple in case of genetic predisposition), confirmation of the diagnosis of PNET, a search for metastases (mainly hepatic), and identification of the main histoprognostic factors. This update focuses on the WHOÂ 2017 histological classification and recent innovations in the preoperative assessment of PNET using conventional and isotopic imaging. The aim is to not only allow the mapping of primary and metastatic lesions but also to predict tumor aggressiveness.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
S. Deguelte, L. de Mestier, O. Hentic, J. Cros, R. Lebtahi, P. Hammel, R. Kianmanesh,